Bio-Techne Aktie
WKN DE: A12ENG / ISIN: US09073M1045
19.10.2023 13:40:05
|
Bio-Techne Promotes Kim Kelderman To Succeed Chuck Kummeth As President And CEO
(RTTNews) - Bio-Techne Corp. (TECH) announced Thursday that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer, effective February 1, 2024. Kelderman will also become a member of the Board of Directors on the same day.
Prior to assuming CEO responsibilities, Kelderman will become Chief Operating Officer, effective November 1, 2023, where he will be responsible for the day-to-day operations of the Company.
Kelderman succeeds Chuck Kummeth, who will be retiring from the company after serving as President, Chief Executive Officer and Board Director for the past 10 years.
Kummeth will continue to provide transition support to Kelderman as a Senior Advisor from February 1, 2024 until his retirement on July 1, 2024.
Kelderman is a proven business leader with more than 30 years of operational and strategic experience. Since joining Bio-Techne in 2018, Kelderman has served as President of its Diagnostics and Genomics Segment (DGS).
Kelderman also currently serves on the Board of Directors of StatLab Medical Products. Prior to joining Bio-Techne, Kelderman led three different businesses of increasing scale and complexity at Thermo Fisher Scientific. Previously, Kelderman served as Senior Segment leader at Becton Dickinson where he managed its global BD Vacutainer business.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
08.05.25 |
S&P 500-Papier Bio-Techne-Aktie: So viel Verlust hätte ein Bio-Techne-Investment von vor einem Jahr eingefahren (finanzen.at) | |
06.05.25 |
Ausblick: Bio-Techne zieht Bilanz zum abgelaufenen Quartal (finanzen.net) | |
01.05.25 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor 10 Jahren verdient (finanzen.at) | |
24.04.25 |
S&P 500-Wert Bio-Techne-Aktie: Hätte sich eine Anlage in Bio-Techne von vor 5 Jahren gerechnet? (finanzen.at) | |
22.04.25 |
Erste Schätzungen: Bio-Techne gewährt Anlegern Blick in die Bücher (finanzen.net) | |
17.04.25 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätte eine Investition in Bio-Techne von vor 3 Jahren gekostet (finanzen.at) | |
10.04.25 |
S&P 500-Wert Bio-Techne-Aktie: So viel Verlust hätte ein Bio-Techne-Investment von vor einem Jahr eingebracht (finanzen.at) | |
03.04.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte eine Bio-Techne-Investition von vor 10 Jahren eingebracht (finanzen.at) |
Analysen zu Bio-Techne Corpmehr Analysen
Aktien in diesem Artikel
Bio-Techne Corp | 45,00 | 0,90% |
|